2025 SPEAKERS
Kevyn Adler, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Eunice Alvazzi, Head of Global Value & Access, Hematology, Nephrology & Neurology,, Alexion – AstraZeneca Rare Disease
Marta Andreykiv, Head of Market Access Europe, Viatris
Luigi Angelillo, Director, Market Access EMEA, Argenx
Ad Antonisse, Director, Market Access & Corporate Affairs, Astrazeneca
Sabrina Aouabed, Head of Market Access France, GSK
Jose Aragunde, Value and Pricing Strategy Lead, Market Access, Novartis
Jorge Arellano, Vice President, Head of Intercontinental Markets, Market Access, Pricing, & Value Demonstration, Bristol Myers Squibb
Marnix Artz, Head, Patient Access, Pricing & Governmental Affairs, Merck Group
Johnny Bane, Head of Market Access, Accord Healthcare
Jasmin Barman-Aksözen, Vice President, International Porphyria Patient Network
Alexander Bastian, Vice President, Commercial Strategy, Memo Therapeutics
Stefano Benvenuti, Head of Public Head of Public Affairs and Market Access, Fondazione Telethon
Tomer Benzaken, Director, Head of Commercial Operations & Trade, Astellas
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, Astrazeneca
Samir Bhattacharyya, Global Vice President, Value Marketing, Health Economics & Market Access, Boston Scientific Corporation
Chris Bidad, Global Head, Access Strategy and Payer Policy, Astrazeneca
Matthias Bischof, Senior Director, International Health Economics, Novartis
Marie-Sharmila Blandino, Global Access Strategy Lead, Amgen
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Angela Borghouts - de Ruijter, Senior Pricing and Market Access Manager, Cell Therapy, Gilead Sciences
Kinga Borsos, Vice President, Head of US HEOR, Boehringer Ingelheim
Okke Bosgra, Director, International Market Access, Natera
Meindert Boysen, Independent HTA Expert & Chair, HTAi Global Policy Forum
Vidya Breeveld, CEO, Transmineo
Chiara Brouns, Strategic purchaser, Zorgverzekeraars Nederland
Henriette Burghoorn, Associate Director, Market Access, Gilead
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Thomas Butt, Executive Director, Health Economics & Outcomes Research, Biomarin
Astrid Buys, Global Head of Tenders & Pricing, Bavarian Nordic
Frederico Calado, Real-World Data Strategic Partnership Lead, Sanofi
Silvia Miriam Cammarata, Senior Regulatory Affairs and Health Policy Specialist, AIFA Italian Medicine Agency
Gorana Capkun, Vice President, Global Head of Patient Focused Real World Evidence, Merck Group
Lorenzo Capretto, Market Access Lead EU&EM, Global Rare Disease, Chiesi Farmaceutici SpA
Joao Carapinha, Director & Professor, Syenza & Northeastern University
Antonella Cardone, CEO, Cancer Patients Europe
Laurent Carter, Senior Vice President, Head of Global Pricing, bristol-myers squibb
Mark Cawley, Associate Director, R&D Procurement, Jazz Pharmaceuticals
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
Helene Chevrou-Severac, Senior Director, RWE & Outcomes Centre of Excellence Head, Alexion – AstraZeneca Rare Disease
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Stephen Connell, Senior Director, Global Pricing & Market Access - Gene Therapy, Pfizer
Warren Cowell, Director, Market Access UK, Shionogi Ltd
Don Creighton, Executive Director, Market Access Pipeline and Readiness Lead, Regeneron
Rishi Das-Gupta, Chief Executive Officer, Health Innovation Network
Dalia Dawoud, Associate Director, Research, NICE
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Emanuele Degortes, Vice President, Global Head of Access Policy and Patient Advocacy, Menarini
Eelko Den Breejen, Sr. Director. Global Access Strategy & Pricing Oncology Team Lead. Portfolio & Market Engagement, Pfizer
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Eva Susanne Dietrich, Professor, Departments for Clinical Pharmacy and Regulatory Affairs, University of Bonn
Toon Digneffe, Head Public Affairs & Public Policy, Takeda
Riad Dirani, Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals
Patricia Dorling, Vice President, Head, Global HEOR and Real World Evidence, Chiesi Group
Maurice Driessen, Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals
Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Shane Elder, Head of Market Access, Europe & Canada, Astrazeneca
Claire Everitt, Design Engineering Team Lead, IMI Project Leader, Pfizer
Gina Ewy, VP, Hansa Biopharma
Marina Faiella, Independent Market Access Expert
Tina Fischer, Head of Health Technology Assessments, Oncology, Daiichi-sankyo
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Steven Flostrand, Executive Director, Value, Access & Pricing, Incyte Corp.
Martina Garau, Director, Office of Health Economics
Loic Gauthier, Director, Market Access and Pricing, Intercontinental Region, CSL Behring
Philippe Ghyssels, Vice President, Global Public Affairs, Ipsen
Mathieu Gilbert, Chief Operating Officer, Adocia
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson
Tristan Gloede, Executive Director, Global Head of Market Access Retinal Health, Boehringer Ingelheim
Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut & Utrecht University
Jean Christophe Goirand, Senior Director, Global Head Market Access & Pricing, Essential Pharma
Sofiya Got, Strategy and Transformation Analyst, NHS
Sylvie Greneche, Head of Global Market Access, General Medicines, Sanofi
Thomas Grub, Senior Expert, Global Pricing and Market Access, medac GmbH
Neil Grubert, Global Market Access Expert, Independent
Josep M Guiu, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Marlene Gyldmark, Vice President, Head, Global Access Evidence, Idorsia
Matthew Hanchard, Research Fellow, University of Sheffield
Günter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Janek Hendrich, Value Strategies Lead, Oncology, AstraZeneca
Patrick Hopkinson, Independent HTA Expert
Martí Hopmans, Senior Global Market Access Manager, Ferrer International
Kirsty Hoyle, Chief Executive Officer, Metabolic Support UK
Dawn Ireland, President & Founder, CDH International
Amy Israel, Senior Advisor, Access to Medicines, Union for International Cancer Control
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Daniel Jackson, Global Head, Payer Evidence Synthesis, UCB
Clare Jamookeeah, Global Director, Global Value Strategies, Oncology Market Access, AstraZeneca
Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Lisette Kaskens, Director Market Access, Ferring Pharmaceuticals
Ankita Kaushik, Senior Director, HEOR, Global Value and Access, Gilead Sciences
Angie Kehagia, Deputy Director, Senior HTA, KiTEC King's Technology Evaluation Centre
Sebastian Kessel, Senior Director, Head of Market Access & Public Affairs, Germany, UCB
Sandeep Kiri, Global Head, Health Economic Evidence, UCB
Sven Klijn, Director, HEOR Economic & Predictive Modeling, Bristol Myers Squibb
Tomasz Kluszczynski, Strategy Consultant & Founder, ACESO Healthcare
Helen Knight, Director of Medicines Evaluation, NICE
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Amit Kulkarni, Head of Health Economic Modeling and Decision Sciences, Otsuka
Hannah Kurth, Founder and Managing Director, Pulse Edge
Marianne Laouri, Executive Director, Global Asset Lead, Retinal Health, Boehringer Ingelheim
Walmon Leal, Vice President, Head of Global Pricing, Tenders & Contract, Viatris
Pauline L'Hénaff, Head of Industry Engagement, Access to Medicine Foundation
Manuela Machado, Head of Market Access Europe, UCB
Jörg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Charles Makin, Head of RWE, Boehringer Ingelheim
Bill Malcolm, Executive Director, Global HEOR Economic & Predictive Modelling, BMS
Chris Mancill, Senior Vice President, Head, US Market Access, AstraZeneca
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Sandra Margunato-Debay, Senior Director, Global Market Access, genmab
Marisca Marian, Oncology Market Access, Strategy Lead, Bayer
Alen Marijam, Senior Director, Vaccines, HEOR and Epidemiology Lead, Europe, GSK
Jake McDowell, Vice President, Head of Market Access and Pricing, Partner Therapeutics
Vanessa Mirsky, Vice President, Life Sciences Data Strategy, OneOncology
Lorenzo Montrasio, Member of Volrethics Steering Committee, Former Council of Europe
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Philippe Mourouga, Vice President, International Partner Markets, Biogen
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Antonia Needham-Taylor, Health Services Researcher, Health Technology Wales
Sandra Nestler-Parr, Vice President, Value & Access, BioCryst Pharmaceuticals
Anh Bourcet Nguyen, Senior Director, Market Access & Public Affairs, APAC, Novo Nordisk
Enkeleida Nikai, Vice President, Head of Global Real-World Evidence, GenMed, Sanofi
Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Melvin Skip Olson, Founder, Olson Strategies GmbH
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Wija Oortwijn, Chair of Appraisal Committee at ZINL & Assistant Professor, HTA, ZIN & Radboud University Medical Center
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Robert Palmer, Head of Access, Oncology, Boehringer Ingelheim
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Lucia Paone, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Lotta Parviainen, Head of Global Market Access, Zambon France
Dilip Patel, SVP, Pricing, Value & Access Strategy, Autolus
Julien Patris, Head of Patient Advocacy, Public Policy, Corporate Communications, EMEA, arGEN-X
Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boeringer Ingelhiem
Tomaso Piaggio, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Oresta Piniazhko, Director, Hta Department, Ministry of Health, Ukraine
Carme Pinyol, Early Products and HEOR Lead, Novartis
Lara Pippo, Head of Market Access & Government Affairs, Italy, CSL Behring
Julie Powell, Director, Patient Advocacy and Public Affairs, Pleco Therapeutics
Annette Powers, Senior Vice President, Global Market Access, Bristol Myers Squibb
Arup Pramanik, Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim
Chris Prins, Policy Advisor Expensive Medicines, Zorgverzekeraars Nederland
Jennifer Quinn, Head of Global Value and Access, Debiopharm international
Laurene Redding, Global Head, Value, Access & Pricing, BeiGene
Vijay Reddy, Chief Commercial Officer, Avinya Biotech
Casey Rhode, Head of Strategy, OneOncology
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Claus Runge, Chief Health Equity Officer, Senior Vice President, Global Head of Public Affairs, Sustainability & Int. Engagement, Bayer
Geraldine Rylander, Director, Global Market Access, Psychiatry & Pipeline, Lundbeck
Bettina Ryll, Founder, Melanoma Patient Network Europe, MPNE
José Luis Sánchez, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Marie Sanderson, Head of Value and Access, Innovative Medicine, Novartis
Steve Sandor, Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals , Inc.
Gustavo Saraiva dos Anjos, Head of Pricing and Market Access Europe, TEVA
Fabian Schmidt, Global Head of Market Access, HEOR and Policy, Recordati Rare Diseases
Mette Schrøder Hemels, Vice President, Global Payer Evidence, Portfolio Strategy, Access & Pricing, Novo Nordisk A/S
Ayman Semaan, Market Access & Pricing Lead, Biologix
Shuvayu Sen, Vice President, Head of Oncology, Center of Observational & Real-World Evidence, Merck & Co., Inc.
Hans Severens, Independent HTA Expert, Severens HTA Consultancy
Simon Shohet, Vice President, International Market Access, Amicus Therapeutics
Anupama Rao Singh, Group Country Head -LATAM | Head - Oncology and Hospital Business CoE, Emerging Markets, Dr. Reddy's Laboratories Ltd.
Diana Sinkevich, Head of Access, EU & International, Global Rare Diseases, Chiesi
Matt Slabbert, Vice President, Global Head of Public Affairs, Astellas
Najib Slassi, Director, Global Product Strategy, Novartis
Jiri Smejkal, Head of Pricing and Tender Excellence PDT, Takeda
Igor Solev, Global Head, Market Access, Policy & External Payer Affairs, Abbott Laboratories
Seema Sondhi, Independent Market Access Expert
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Lotte Steuten, Deputy CEO, Office of Health Economics
Rachel Studer, Global Evidence Executive Director, Oncology & Immunology, Novartis
Meni Styliadou, Vice President Global Leader, Health Data Partnerships, Data Science Institute, Takeda Pharmaceuticals International AG
Jan Swiderski, Director, Head of Global Public Affairs and Advocacy, Ipsen
Giovanni Tafuri, Director, EU Market Access and Policy, Apellis Pharmaceuticals
Peter Takacs, Head of Global Market Access, Miltenyi Biomedicine
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Mondher Toumi, Professor of Public Health, Aix-Marseille University
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Emmanouil Tsiasiotis, Research Project Manager and Coordinator, EDiHTA
Kaan Tunceli, Vice President and Head, Global Value and Real World Evidence, Otsuka Pharmaceutical
Aodan Tynan, Vice President, Global Market Access, Astellas
Cristina Valencia, Associate Director, Real World Evidence, Takeda
Bart Van Den Daele, Director, Market Access, Head of External Affairs, Gilead Sciences
Goedele van Haasteren, Deputy Chief of the HTA department, Federal Office of Public Health, Switzerland
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Matthijs Van Meerveld, Associate Vice President, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline
Mary Lynne van Poelgeest-Pomfret, President, World Federation for Incontinence and Pelvic Problems (WFIPP)
Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Johnson & Johnson Innovative Medicine
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Reg Waldeck, Vice President, Oncology Market Access Strategy Leader, Bayer
Alexander Wilke, Senior Director, Global Market Access and Pricing, Norgine
Amy Winnen, Consultant, Independent Market Access Expert
Schiffon Wong, Vice President and Head, Neurology & Immunology, Global Value Demonstration, EMD Serono
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Get Involved
Sponsorship & Exhibition Sales
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
Conference Production
George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940
Marketing Opportunities
Karen Duncan
karen.duncan@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events